Press Release: Source Biomagnetics Diagnostics Corporation

Biomagnetics Diagnostics Approved for Listing in Standard & Poor's Corporate Records Wednesday January 24, 9:01 am ET

ORANGEVALE, Calif.--(BUSINESS WIRE)--January 24, 2007--Biomagnetics Diagnostics Corp. (OTC: BMGP - News) announced today that the Standard & Poor's Editorial Board approved the Company for a complete corporate listing and description in Standard & Poor's Corporate Records. Additionally, Biomagnetics Diagnostics will have its corporate description published in Standard & Poor's Daily News Section.

Standard Corporate Records is a recognized securities manual for "Blue Sky" Standard Manual Exemption trading in approximately 37 states. Biomagnetics's listing in Standard Corporate Records should assist the brokerage and investment communities in the United States in making a market for Biomagnetics's stock. However, it is recommended that brokers check with the applicable "Blue Sky" laws and regulations in their given state.

Clayton Hardman, President and CEO of Biomagnetics Diagnostics, states, "We are very pleased to receive approval for listing in Standard & Poor's Corporation Records which will provide additional transparency and sources of information about our business to our stockholders and to the investment community. The S&P listing is also a key step toward our goal of listing on a senior exchange."

About Biomagnetics Diagnostics Corporation

Biomagnetics Diagnostics Corporation, through its wholly owned subsidiary, Biospectrum Technologies, Inc., a company that has designed and patented revolutionary diagnostic equipment and immunoassays, will identify market inadequacies and fill those needs with new technologies, and highly specific and sensitive assays that are qualitative (yes/no) and quantitative (viral load/degree of infection), easily performed and cost effective.

For more information please visit: www.biomagneticsbmgp.com

Forward-Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Contact: Paul Hardman, (916) 987-7078
Source: BioMag Corp.